Ledger.Open graph →
SEC Form D · filed April 3, 2024

Enliven Therapeutics, Inc

Offering
$90.0M
Sold
$90.0M
Exemption
Rule 506(b)
Industry
Pharmaceuticals
Location
BOULDER, CO
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (22)

Andrew P. Phillips · Boulder, CODirectorRahul P. Ballal · Boulder, CODirectorSamuel Kintz · Boulder, COExec · DirectorHelen P. Collins · Boulder, COExecRichard P. Heyman · Boulder, CODirectorMika P. Derynck · Boulder, CODirectorBenjamin P. Hohl · Boulder, COExecAnish P. Patel · Boulder, COExecJoseph P. Lyssikatos · Boulder, COExec · DirectorJake P. Bauer · Boulder, CODirectorRishi P. Gupta · Boulder, CODirectorHelen P. Collins · Boulder, COExecAndrew P. Phillips · Boulder, CODirectorRichard P. Heyman · Boulder, CODirectorMika P. Derynck · Boulder, CODirectorBenjamin P. Hohl · Boulder, COExecAnish P. Patel · Boulder, COExecJoseph P. Lyssikatos · Boulder, COExec · DirectorJake P. Bauer · Boulder, CODirectorRahul P. Ballal · Boulder, CODirectorRishi P. Gupta · Boulder, CODirectorSamuel Kintz · Boulder, COExec · Director

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗